A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles

Yun Xing^{1,2}
Xiao-Zhen Feng²
Lipeng Zhang¹
Jiating Hou²
Guo-Cheng Han²
Zhencheng Chen²

¹Henan Province of Key Laboratory of New Optoelectronic Functional Materials, College of Chemistry and Chemical Engineering, Anyang Normal University, Anyang, ²School of Life and Environmental Sciences, Guilin University of Electronic Technology, Guilin, Guangxi, People's Republic of China

Abstract: Soluble beta-amyloid (A β) oligomer is believed to be the most important toxic species in the brain of Alzheimer's disease (AD) patients. Thus, it is critical to develop a simple method for the selective detection of A β oligomer with low cost and high sensitivity. In this paper, we report an electrochemical method for the detection of A β oligomer with a peptide as the bioreceptor and silver nanoparticle (AgNP) aggregates as the redox reporters. This strategy is based on the conversion of AgNP-based colorimetric assay into electrochemical analysis. Specifically, the peptide immobilized on the electrode surface and presented in solution triggered together the in situ formation of AgNP aggregates, which produced a well-defined electrochemical signal. However, the specific binding of A β oligomer to the immobilized peptide prevented the in situ assembly of AgNPs. As a result, a poor electrochemical signal was observed. The detection limit of the method was found to be 6 pM. Furthermore, the amenability of this method for the analysis of A β oligomer in serum and artificial cerebrospinal fluid (aCSF) samples was demonstrated.

Keywords: electrochemical biosensors, Alzheimer's disease, beta-amyloid oligomer, peptide, silver nanoparticles

Introduction

Alzheimer's disease (AD), the most common neurodegenerative disorder, will affect ~66 million people globally by the year 2030.¹ A hallmark of AD is the deposition of the beta-amyloid (A β) peptide in the brain.^{2,3} A β monomer, typically comprising 39–43 amino acid residues, results from proteolytic cleavage of amyloid precursor protein (APP) by β - and γ -secretase.⁴ Furthermore, the monomers can coalesce to form small, soluble oligomeric species and then assemble into higher molecular weight fibrils. Thus, A β monomer and its aggregates have been considered not only as a therapeutic target but also as a diagnostic marker.^{5–9} There are many methods for the detection of A β monomer with high sensitivity, such as electrochemical immunosensors, colorimetric assays, resonance light scattering and surface plasmon resonance.^{10–18} However, assay of A β monomer only might be unable to discriminate between AD patients and healthy controls or other types of dementia because the levels of A β monomer may differ by gender and age.¹⁹ Soluble A β oligomer comprising 50–100 A β monomers is believed to be neurotoxic and responsible for neuronal death in preclinical AD.^{20,21} In addition, elevated levels of A β oligomer have been detected in the cerebrospinal fluid (CSF) of AD patients.^{22,23} Therefore, the direct detection of

Correspondence: Guo-Cheng Han
School of Life and Environmental
Sciences, Guilin University of Electronic
Technology, Jinji Road, No. 1, Guilin,
Guangxi 541004, People's Republic of
China
Email yunxinghxx@163.com

A β oligomer level would be more reliable for AD diagnosis than assay of its monomer.^{24,25}

Recently, a few novel biosensors have been developed for the detection of A β oligomer, including electrochemistry,^{26–29} surface plasma resonance (SPR),³⁰ localized surface plasmon resonance (LSPR),^{24,31} fluorescence,^{32,33} nuclear magnetic resonance,³⁴ and surface-enhanced Raman spectroscopy.³⁵ These methods are feasible, but they require the use of special instruments and/or relatively expensive and variable antibodies for the capture and recognition of A β oligomer. Moreover, the reported antibody of A β oligomer also recognizes A β monomer and other A β aggregates and metabolites to some extent.³⁶ Alternatively, the organic dye-based fluorescence assays (eg, thioflavin T [ThT]) have been commonly used for monitoring the formation of A β aggregates in laboratory investigation.^{37,38} However, most of the dyes cannot be used to discriminate A β oligomer from other β -sheets of A β aggregates,³⁷ thus limiting their applications for the routine test of A β oligomer for early diagnosis of AD.

Cellular prion protein (PrP^C) is a membrane-bound glycoprotein present in the central nervous system. There is increasing evidence demonstrating that PrP^C may be a high-affinity receptor for A β oligomer.^{39–44} The core region of PrP^C to bind with A β oligomer is PrP_{95–110}, which is located within the unstructured N-terminal region of PrP^C with an amino acid sequence of THSQWNKPSKPKTNMK (PrP_{95–110}).^{39,42–45} The dissociation constant (K_d) for the A β oligomer/PrP_{95–110} interaction is in the subnanomolar range, and the interaction is highly specific for A β oligomer, but not for its monomer

and fibril.^{42,43,46} These results provide researchers a hint that PrP_{95–110} would be a good receptor for the design of novel biosensors for A β oligomer detection.

In recent years, metal nanoparticles (MNPs) have been widely used for creating effective recognition and transduction processes in chem/biosensing due to their unique physicochemical attributes.^{47–59} In particular, silver nanoparticles (AgNPs) offer clear advantages for the design of electrochemical (bio) sensors, such as a simple preparation procedure, a size-dependent optical property, facile surface modification, a high surface area and a low oxidation potential.^{55–59} Based on the specific A β oligomer/PrP_{95–110} interaction and the well-defined and signal-amplified electrochemical signal of AgNP aggregates, Xia et al⁵⁹ have developed an electrochemical biosensor for the determination of A β oligomer by using adamantine (Ad)-labeled PrP_{95–110} (Ad-PrP_{95–110}) as the receptor and AgNP aggregates as the redox reporters. In this work, the network architecture of Ad-PrP_{95–110}/AgNP nanocomposites produced in solution was introduced onto the β -cyclodextrin (β -CD)-modified electrode surface through the host–guest interaction (Scheme 1). The specific A β oligomer/PrP_{95–110} interaction made the Ad-PrP_{95–110} in solution to lose its capability to trigger the formation of AgNPs-based network architecture. This work presented a concept for converting the AgNPs-based colorimetric assay into a sensitive electrochemical analysis by simply incorporating the colorimetric principle into the electrochemical platform. The method is simple and does not require the modification of analyte-binding molecules onto the surface of nanoparticles. However, it requires the modification

Scheme 1 Schematic illustration of the previous electrochemical strategies for the detection of A β oligomer with PrP_{95–110} as the receptor and AgNP aggregates as the redox reporters.

Abbreviations: A β , beta-amyloid; PrP, prion protein; AgNP, silver nanoparticle; Ad, adamantine; β -CD, β -cyclodextrin.

of both electrode and peptide probe. More importantly, the unmodified method showed poor anti-interference ability to high concentration of salts and other components in body fluids, thus failing to determine A β oligomer in biological samples. In the present study, we reported an innovative electrochemical method for the detection of A β oligomer based on the in situ formation of AgNP aggregate tags. As shown in Scheme 2, PrP₉₅₋₁₁₀ immobilized on the electrode surface and presented in solution triggered together the in situ formation of AgNP aggregates, which produced a well-defined electrochemical signal. Once the electrode was covered with A β oligomer, PrP₉₅₋₁₁₀ on the electrode surface would lose its ability to trigger the in situ formation of AgNPs-based network architecture. To avoid the absorption of other components onto the surface of unmodified AgNPs in the real sample analysis, the competitive assay was performed by a two-step procedure: incubation of the sensing electrode with A β oligomer sample first and follow-up incubation with AgNPs/PrP₉₅₋₁₁₀. The proposed strategy not only features simple manipulation principle similar to that of colorimetric assay but also shows high sensitivity and specificity of electrochemical biosensor.

Experimental section

Chemicals and materials

Peptides with the sequences of CTHSQWNKPSKPKTNMK and THSQWNKPSKPKTNMK (PrP₉₅₋₁₁₀) were synthesized and purified by Synpeptide Co., Ltd (Shanghai, China). The A β peptide with 42 amino acid residues (A β ₁₋₄₂), 6-mercapto-1-hexanol (MCH), tris(2-carboxyethyl)phosphine (TCEP), bovine

serum albumin (BSA), immunoglobulin G (IgG), lysozyme, thrombin, serum and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). All other chemicals were of analytical grade and provided by Beijing Chemical Reagent Co. Ltd (Beijing, China).

Citrate-stabilized AgNPs and soluble A β oligomer were prepared as in our previous report.⁵⁹ Artificial cerebrospinal fluid (aCSF) used in the determination of the samples was prepared by 150 mM NaCl, 3 mM KCl, 1.4 mM CaCl₂, 1 mM phosphate and 0.8 mM MgCl₂.^{29,60}

Instruments

The ultraviolet (UV)/visible (Vis) spectra were collected on a Cary 60 spectrophotometer using a 1-cm quartz spectrophotometer cell. The atomic force microscopy (AFM) images were taken using a Dimension Edge microscope (Bruker Nano Inc., Santa Barbara, CA, USA) equipped with a tapping mode. The transmission electron microscope (TEM) images were taken using an FEI Tecnai G2 T20 TEM (Hillsboro, OR, USA). The electrochemical experiments were carried out using a CHI-660E (CH Instruments, Shanghai, China) electrochemical workstation. Platinum wire was used as the auxiliary electrode. The reference electrode was Ag/AgCl.

Stability of AgNPs

To examine the inhibition of A β oligomer on the PrP₉₅₋₁₁₀-triggered assembly of AgNPs, PrP₉₅₋₁₁₀ was mixed with A β oligomer for 10 min. Then, AgNPs suspension was added to the PrP₉₅₋₁₁₀ solution. After incubation for 5 min, color change

Scheme 2 Schematic illustration of the present electrochemical strategies for the detection of A β oligomer with PrP₉₅₋₁₁₀ as the receptor and AgNP aggregates as the redox reporters.

Abbreviations: A β , beta-amyloid; PrP, prion protein; AgNP, silver nanoparticle.

was observed with the naked eye and the photograph was taken by a digital camera. UV/Vis absorption spectra were collected using the spectrophotometer.

Electrochemical detection of A β oligomer

The cleaned gold disk electrode with a diameter of 2 mm was placed in a 100 μ L phosphate-buffered saline (PBS) solution (10 mM, pH 7.2) containing 10 μ M thiolated PrP₉₅₋₁₁₀ (CTHSQWNKPSKPKTNMK) and 50 μ M TCEP overnight. After the formation of peptide self-assembled monolayers (SAMs), the electrode was washed with water and then soaked in a 1 mM MCH solution for 30 min. For the detection of A β oligomer, the PrP₉₅₋₁₁₀-functionalized electrode was first immersed in a 20 μ L PBS solution containing a given concentration of A β oligomer for 10 min, and the electrode was then rinsed thoroughly with water and exposed to 20 μ L of AgNPs suspension in an opened plastic tube. This step was followed by the addition of 20 μ L of PrP₉₅₋₁₁₀ to incubation for 10 min. After being rinsed with water, the electrode was placed in a 1 M KCl solution for linear sweep voltammetry (LSV) measurement.

Results and discussion

PrP₉₅₋₁₁₀-triggered AgNPs aggregation

As shown in Figure 1A, the AgNPs solution showed an absorption peak at 404 nm (black curve), which is ascribed to the surface plasmon resonance of AgNPs. With the addition of PrP₉₅₋₁₁₀, the original absorbance of AgNPs at 404 nm

decreased, while a new absorbance peak at 525 nm appeared (red curve). The red-shifted band demonstrated that PrP₉₅₋₁₁₀ triggered the aggregation of AgNPs. The aggregation is attributed to the electrostatic interaction between the negatively charged citrate-capped AgNPs and the positively charged lysine residues in PrP₉₅₋₁₁₀.⁵⁹ We also found that the absorption intensity of AgNPs at 525 nm increased and reached a plateau value within 7 min, indicating the achievement of the PrP₉₅₋₁₁₀-triggered AgNPs assembly. When PrP₉₅₋₁₁₀ was first mixed with A β oligomer, only one absorption peak at 404 nm was observed (blue curve) with the addition of the mixed solution to AgNPs suspension. It is indicative of a good dispersion of AgNPs in the presence of the A β oligomer-PrP₉₅₋₁₁₀ complex. Furthermore, these results were confirmed by the TEM observations: aggregated AgNPs in the presence of PrP₉₅₋₁₁₀ only (Figure 1B) and dispersed AgNPs in the presence of A β oligomer/PrP₉₅₋₁₁₀ (Figure 1C). We also found that A β monomer and fibril did not inhibit the PrP₉₅₋₁₁₀-triggered red shift of AgNPs absorbance, which agrees with the previous report.⁵⁹ These results confirmed that only A β oligomer inhibited the PrP₉₅₋₁₁₀-induced assembly of AgNPs, which is contributed to the strict dependence of the recognition of PrP₉₅₋₁₁₀ on the secondary structure of A β .

Electrochemical analysis

Herein, we suggested that PrP₉₅₋₁₁₀ both on electrode and in solution could trigger the in situ formation of AgNP

Figure 1 Characterization of AgNPs in the presence PrP₉₅₋₁₁₀ or A β oligomer/PrP₉₅₋₁₁₀.

Notes: (A) UV-Vis absorption spectra of AgNPs in the absence and presence of PrP₉₅₋₁₁₀ or A β oligomer/PrP₉₅₋₁₁₀. TEM images of AgNPs in the presence of PrP₉₅₋₁₁₀ (B) or A β oligomer/PrP₉₅₋₁₁₀ (C). The concentrations of AgNPs, PrP₉₅₋₁₁₀ and A β sample (equivalent monomer) were 2.4 nM, 0.1 μ M and 2 μ M, respectively.

Abbreviations: UV, ultraviolet; Vis, visible; AgNP, silver nanoparticle; PrP, prion protein; A β , beta-amyloid; TEM, transmission electron microscope.

aggregates on the electrode surface. When PrP₉₅₋₁₁₀ immobilized on the electrode surface interacted with A β oligomer, it lost the ability to trigger the in situ formation of AgNPs-based network architecture. To demonstrate the feasibility of our design, LSV was used to measure the oxidation current of AgNPs. As shown in Figure 2, incubation of the PrP₉₅₋₁₁₀-functionalized electrode with AgNPs/PrP₉₅₋₁₁₀ resulted in the appearance of a well-defined oxidation peak at ~65 mV (black curve), which is attributed to the solid-state Ag/AgCl reaction from AgNPs. However, no oxidation peak was observed when the functionalized electrode was incubated with PrP₉₅₋₁₁₀ itself (red curve), and only a small oxidation peak was observed when the electrode was incubated with AgNPs only (blue curve). These results demonstrated that the strong oxidation peak in the black curve should be attributed to the formation of the AgNPs/PrP₉₅₋₁₁₀ network architecture. When the electrode was incubated with A β oligomer, followed by incubation with PrP₉₅₋₁₁₀/AgNPs (green curve), the current dropped almost to the background level. This indicated that the binding of PrP₉₅₋₁₁₀ to A β oligomer inhibited the in situ formation of AgNPs/PrP₉₅₋₁₁₀ network architecture on the electrode surface. Additionally, we found that a slight decrease in the current was observed (magenta curve) when the sensor electrode was incubated with the mixed solution comprising AgNPs, PrP₉₅₋₁₁₀ and A β oligomer (one-step method). Thus, the two-step method performed

Figure 2 The LSV responses of the PrP₉₅₋₁₁₀-functionalized electrodes after incubation with AgNPs/PrP₉₅₋₁₁₀ (black curve), PrP₉₅₋₁₁₀ (red curve), AgNPs (blue curve), A β oligomer and AgNPs/PrP₉₅₋₁₁₀ (green curve) and the mixture of A β oligomer/PrP₉₅₋₁₁₀/AgNPs (magenta curve).

Notes: The arrow indicates the scan direction. The concentrations of AgNPs, PrP₉₅₋₁₁₀ and A β sample were 2.4 nM, 0.1 μ M and 2 μ M, respectively.

Abbreviations: LSV, linear sweep voltammetry; PrP, prion protein; AgNP, silver nanoparticle; A β , beta-amyloid.

by incubation of the sensor electrode with A β oligomer first and follow-up incubation with AgNPs/PrP₉₅₋₁₁₀ (green curve) is more sensitive than the one-step method. The result is understandable since large amount of PrP₉₅₋₁₁₀ in solution would preferentially bind to A β oligomer, thus hampering the formation of A β oligomer/PrP₉₅₋₁₁₀ on the electrode surface and facilitating the in situ assembly of AgNPs. Furthermore, other components in biological samples may absorb on the surface of unmodified AgNPs to reduce the selectivity of biosensor.⁵⁹ Therefore, the competitive assay was performed by the two-step procedure.

Optimization of experimental conditions

A higher concentration of PrP₉₅₋₁₁₀ can make the aggregation of AgNPs more powerful. However, a higher concentration of PrP₉₅₋₁₁₀ in solution would compete with the anchored PrP₉₅₋₁₁₀ on the electrode surface to bind with AgNPs, thus hampering the in situ formation of the AgNPs/PrP₉₅₋₁₁₀ network architecture. Thus, we first investigated the effect of the concentration ratio of PrP₉₅₋₁₁₀ to AgNPs ([PrP₉₅₋₁₁₀]/[AgNPs]) on the oxidation current (I_{pa}). It was found that I_{pa} initially increased with the increasing [PrP₉₅₋₁₁₀]/[AgNPs] ratio until the maximal value appeared at 83:1 (Figure 3A). Furthermore, the dependence of I_{pa} on the AgNPs concentration was examined. It was found that I_{pa} increased upon increasing concentrations of AgNPs and began to level off beyond 1.2 nM (Figure 3B). Thus, in the following quantitative assays of A β oligomer, the concentrations of AgNPs and PrP₉₅₋₁₁₀ were kept at 1.2 and 100 nM, respectively.

With the increase in incubation time, A β monomers can assembly spontaneously into oligomeric and fibrous species. We also studied the influence of A β incubation time on the formation of A β oligomer and the inhibition of PrP₉₅₋₁₁₀-triggered assembly of AgNPs. As shown in Figure 4, the lowest points of the currents are in the range of 16–24 h, indicating the optimal incubation time for the formation and detection of A β oligomer. In the following quantitative assays, 20 h was set as the optimized time for oligomer preparation.

Sensitivity and selectivity

Under the optimized experimental conditions, the quantitative detection of A β oligomer was performed. As shown in Figure 5A, I_{pa} decreased with increasing A β oligomer concentration ([A β], equivalent monomer) varying from 0 to 2 μ M. The relative standard deviations (RSDs) are all <13% for assay of the same A β oligomer sample at three different electrodes in parallel. The acceptable reproducibility demonstrated that multiple electrodes can be

Figure 3 Dependence of the current on the concentration ratio of PrP₉₅₋₁₁₀ to AgNPs (A) and the AgNPs concentration (B).

Notes: In (A), the AgNPs concentration was kept at 2.4 nM and the concentration of PrP₉₅₋₁₁₀ was increased from 0.05 to 0.5 μM (0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 μM). In (B), the concentration ratio of PrP₉₅₋₁₁₀ to AgNPs was kept at 83:1 and the AgNPs concentration was increased from 0.15 to 4.8 nM (0.15, 0.3, 0.45, 0.9, 1.2, 2.4 and 4.8 nM). I_{pa} , oxidation current.

Abbreviations: PrP, prion protein; AgNP, silver nanoparticle; A β , beta-amyloid.

prepared concurrently for the analysis of many different samples. Herein, the current change ΔI_{pa} ($I_{pa} - I'_{pa}$, where I_{pa} and I'_{pa} represent the current in the absence and presence of A β oligomer, respectively), was used to evaluate the sensor performances. As shown in the inset, ΔI_{pa} is proportional to [A β] in a linear range of 0.01–200 nM. The regression equation was found to be $\Delta I_{pa} = 0.289 + 0.045 [A\beta]$ (nM). The detection limit was estimated to be 6 pM by measuring the sensor response to a dilution series and determining the target smallest concentration at which the sensor response is

clearly distinguishable from the response to a blank solution. This value is comparable to that achieved by the AgNPs- or AuNPs-based LSPR techniques (0.1 or 1.5 pM),^{24,31} and is significantly lower than that achieved by other methods, including molecular beacon (MB; 3.57 nM)-based,⁶ graphene oxide (1 nM)-based and CdTe quantum dots (QDs)-based fluorescent assays,⁴⁶ square wave voltammetry (48 pM),²⁷ electrochemical impedance spectroscopy (100 pM),⁴⁵ magnetic bead-droplet immunoassay (2.22 mM)⁶¹ and surface-enhanced Raman spectroscopy (0.1 μM).³⁵ Moreover, our

Figure 4 Influence of A β incubation time on the formation of A β oligomer and the current.

Notes: (A) Dependence of the current on the incubation time for the preparation of A β oligomer. The final concentrations of AgNPs, PrP₉₅₋₁₁₀ and A β sample were kept at 1.2 nM, 100 nM and 1 μM , respectively. (B) AFM images of the mica substrate after incubation with A β samples pre-incubated for 24 and 48 h. I_{pa} , oxidation current.

Abbreviations: A β , beta-amyloid; AgNP, silver nanoparticle; PrP, prion protein; AFM, atomic force microscopy.

Figure 5 Sensitivity and selectivity.

Notes: (A) Dependence of the current on the concentration of A β sample (0.01, 0.2, 5, 50, 200, 500 and 2,000 nM). The inset shows the linear dependence of the current change on the concentration of the A β sample. (B) Selectivity of the sensing protocol (bar 1, A β monomer; bar 2, A β fibril; bar 3, A β oligomer; bar 4, BSA; bar 5, IgG and bar 6, thrombin). The concentration of the A β sample was 200 nM and that of BSA, IgG and thrombin was 1 μ M. I_{pa} , oxidation current.

Abbreviations: A β , beta-amyloid; BSA, bovine serum albumin; IgG, immunoglobulin G.

method required very simple sample handling procedure and obviated the modification of nanoparticles and the utilization of expensive and variable antibodies for the capture and recognition of A β oligomer. The physiological content of A β in a normal human CSF is in the range of nanomolar, and a higher concentration of A β oligomer is present in AD patients.² Thus, the proposed method is promising to detect A β oligomer in body fluids.

To explore the specificity of our method, A β monomer, A β fibril and three interfering proteins (BSA, IgG and thrombin,) were tested. As shown in Figure 5B, compared to the control, only the fibril control caused a significant change in the current. This is probably due to the existence of a small amount of unfibrillar oligomer in the solution. The other four interferences did not cause significant change in the current. The result demonstrated that the tested interferences did not prevent the assembly of AgNPs/PrP₉₅₋₁₁₀ on the sensor surface. Therefore, the proposed electrochemical method showed extraordinary selectivity toward the detection of A β oligomer. The high selectivity could be principally attributed to the strong and specific binding capacity of PrP₉₅₋₁₁₀ to A β oligomer.

Assay of A β oligomer in serum and aCSF

To demonstrate the viability of our method for real sample assay, the content of A β oligomer in aCSF and 20% serum was determined by the standard addition method. The accuracy of the assay was evaluated by determining the recovery for the spiked sample. As shown in Table 1, the recoveries for assays of three different concentrations of A β oligomer varied from 86% to 109%. The acceptable values implied

that the proposed method could provide a potential platform for the detection of A β oligomer in CSF and serum samples of AD patients.

Conclusion

This work presented an innovative electrochemical method for the detection of A β oligomer by inhibiting the in situ formation of AgNPs-based network architecture on the electrode surface. The A β oligomer-binding peptide was used as the recognition element. The proposed electrochemical method not only features simple manipulation principle and easy detection procedure similar to that of colorimetric assay but also shows high sensitivity and specificity. The detection limit of this method for A β oligomer detection is 6 pM, which is comparable to or lower than that achieved by the previously reported methods. However, our method is rapid (<30 min) and label free, obviates the modification of nanoparticles for signal amplification and does not require the utilization of expensive and variable antibodies and enzymes for the capture and recognition of A β oligomer. In view of the high

Table 1 Results of the proposed method for the detection of A β oligomer in aCSF and serum

Sample	Added (nM)	Found (nM)	Recovery (%)
1 (aCSF)	1	0.89	89
2 (aCSF)	20	21.8	109
3 (aCSF)	50	52.4	104.8
4 (serum)	1	0.86	86
5 (serum)	20	17.9	89.5
6 (serum)	50	43.7	91.4

Abbreviations: A β , beta-amyloid; aCSF, artificial cerebrospinal fluid.

toxicity of soluble A β oligomer in the brains of AD patients, the proposed biosensor could potentially serve as a viable alternative for facile clinical diagnosis of AD. The result also demonstrated that the bare AgNPs-based colorimetric assay can be converted into an electrochemical analysis with improving specificity. Moreover, this proposed detection principle should be valuable for developing label-free optical platforms with multiplexed aptameric peptide microarrays.

Acknowledgment

Partial support of this work by the National Natural Science Foundation of China (nos 61661014 and 61301038) and the Natural Science Foundation of Guangxi Province (no 2015GXNSFBA139041) is gratefully acknowledged.

Disclosure

The authors report no conflicts of interest in this work.

References

- Wortmann M. Dementia: a global health priority-highlights from an ADI and world health organization report. *Alzheimers Res Ther.* 2012; 4(5):40.
- Hamley IW. The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. *Chem Rev.* 2012;112:5147–5192.
- Heo CH, Kim KH, Kim HJ, et al. A two-photon fluorescent probe for amyloid-beta plaques in living mice. *Chem Commun.* 2013;49: 1303–1305.
- Xia N, Zhang YJ, Guan PP, Hao YQ, Liu L. A simple and label-free electrochemical method for detection of beta-site amyloid precursor protein cleaving enzyme and screening of its inhibitor. *Sens Actuat B Chem.* 2015;213:111–115.
- de la Escosura-Muñiza A, Plichtab Z, Horákb D, Merkočia A. Alzheimer's disease biomarkers detection in human samples by efficient capturing through porous magnetic microspheres and labelling with electrocatalytic gold nanoparticles. *Biosens Bioelectron.* 2015;67: 162–169.
- Zhu LL, Zhang JY, Wang FY, et al. Selective amyloid β oligomer assay based on a basic site-containing molecular beacon and enzyme-free amplification. *Biosens Bioelectron.* 2016;78:206–212.
- Vieira DB, Gamarra LF. Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier. *Int J Nanomed.* 2016;11:5381–5414.
- Zaman M, Ahmad E, Qadeer A, Rabbani G, Khan RH. Nanoparticles in relation to peptide and protein aggregation. *Int J Nanomed.* 2014; 9:899–912.
- Mitatha S, Moongfangklang N, Jalil MA, et al. Proposal for Alzheimer's diagnosis using molecular buffer and bus network. *Int J Nanomed.* 2011;6:1209–1216.
- Rama EC, Gonzalez-Garcia MB, Costa-Garcia A. Competitive electrochemical immunosensor for amyloid-beta 1–42 detection based on gold nanostructured screen-printed carbon electrodes. *Sens Actuat B Chem.* 2014;201:567–571.
- Carneiro P, Loureiro J, Delerue-Matos C, Morais S, Pereira MD. Alzheimer's disease: development of a sensitive label-free electrochemical immunosensor for detection of amyloid beta peptide. *Sens Actuat B Chem.* 2017;239:157–165.
- Hu T, Chen CX, Huang GM, Yang XR. Antibody modified-silver nanoparticles for colorimetric immuno sensing of A beta((1–40/1–42)) based on the interaction between beta-amyloid and Cu²⁺. *Sens Actuat B Chem.* 2016;234:63–69.
- Wang C, Liu D, Wang Z. Resonance light scattering as a powerful tool for sensitive detection of β -amyloid peptide by gold nanoparticle probes. *Chem Commun.* 2011;47:9339–9341.
- Xia N, Liu L, Harrington MG, Wang J, Zhou F. Regenerable and simultaneous surface plasmon resonance detection of A β (1–40) and A β (1–42) peptides in cerebrospinal fluids with signal amplification by streptavidin conjugated to an N-terminus-specific antibody. *Anal Chem.* 2010;82:10151–10157.
- Liu L, He Q, Zhao F, et al. Competitive electrochemical immunoassay for detection of β -amyloid (1–42) and total β -amyloid peptides using p-aminophenol redox cycling. *Biosens Bioelectron.* 2014;51: 208–212.
- Liu L, Zhao F, Ma F, et al. Electrochemical detection of β -amyloid peptides on electrode covered with N-terminus-specific antibody based on electrocatalytic O₂ reduction by A β (1–16)-heme-modified gold nanoparticles. *Biosens Bioelectron.* 2013;49:231–235.
- Yu Y, Zhang L, Li C, et al. A method for evaluating the level of soluble β -amyloid (1–40/1–42) in Alzheimer's disease based on the binding of gelsolin to β -amyloid peptides. *Angew Chem.* 2014;126: 13046–13049.
- Han SH, Chang YJ, Jung ES, Kim JW, Na DL, Mook-Jung I. Effective screen for amyloid β aggregation inhibitor using amyloid β -conjugated gold nanoparticles. *Int J Nanomedicine.* 2011;6:1–12.
- Golde TE, Eckman CB, Younkin SG. Biochemical detection of A beta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. *Biochim Biophys Acta.* 2000;1502:172–187.
- Glabe CG. Structural classification of toxic amyloid oligomers. *J Biol Chem.* 2008;283(44):29639–29643.
- Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature.* 2002;416(6880):535–539.
- Fukamoto H, Tokuda T, Kasai T, et al. High-molecular-weight β -amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. *FASEB J.* 2010;24:2716–2726.
- Hölttä M, Hansson O, Andreasson U, et al. Evaluating amyloid- β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. *PLoS One.* 2013;8:e66381.
- Haes AJ, Chang L, Klein WL, Duyne RPV. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. *J Am Chem Soc.* 2005;127:2264–2271.
- Arosio P, Cukalevski R, Frohm B, Knowles TPJ, Linse S. Quantification of the concentration of A β 42 propagons during the lag phase by an amyloid chain reaction assay. *J Am Chem Soc.* 2014;136(1):219–225.
- Veloso AJ, Chow AM, Ganesh HVS, et al. Electrochemical immunosensors for effective evaluation of amyloid-beta modulators on oligomeric and fibrillar aggregation processes. *Anal Chem.* 2014;86(10): 4901–4909.
- Li H, Xie H, Cao Y, Ding X, Yin Y, Li G. A general way to assay protein by coupling peptide with signal reporter via supermolecule formation. *Anal Chem.* 2013;85(2):1047–1052.
- Zhou YL, Liu LT, Hao YQ, Xu MT. Detection of A β monomers and oligomers: early diagnosis of Alzheimer's disease. *Chem Asian J.* 2016; 11:805–817.
- Zhou Y, Zhang H, Liu L, et al. Fabrication of an antibody-aptamer sandwich assay for electrochemical evaluation of levels of β -amyloid oligomers. *Sci Rep.* 2016;6:35186.
- Yi XY, Feng CT, Hu SQ, Li HF, Wang JX. Surface plasmon resonance biosensors for simultaneous monitoring of amyloid-beta oligomers and fibrils and screening of select modulators. *Analyst.* 2015;141(1): 331–336.
- Kang MK, Lee J, Nguyen AH, Sim SJ. Label-free detection of ApoE4-mediated β -amyloid aggregation on single nanoparticle uncovering Alzheimer's disease. *Biosens Bioelectron.* 2015;72:197–204.
- Park MC, Kim M, Lim GT, et al. Droplet-based magnetic bead immunoassay using microchannel connected multiwell plates (μ CHAMPs) for the detection of amyloid beta oligomers. *Lap Chip.* 2016;16: 2245–2253.

33. Esparza TJ, Zhao H, Cirrito JR, et al. Amyloid-beta oligomerization in Alzheimer dementia vs. high pathology controls. *Ann Neurol*. 2013; 73:104–119.
34. Espargaró A, Busquets MA, Estelrich J, Sabate R. Amyloids in solid-state nuclear magnetic resonance: potential causes of the usually low resolution. *Int J Nanomedicine*. 2015;10:6975–6983.
35. Guerrini L, Arenal R, Mannini B, et al. SERS detection of amyloid oligomers on metallorganic-decorated plasmonic beads. *ACS Appl Mater Interfaces*. 2015;7(18):9420–9428.
36. Tsukakoshi K, Abe K, Sode K, Ikebukuro K. Selection of DNA aptamers that recognize α -synuclein oligomers using a competitive screening method. *Anal Chem*. 2012;84:5542–5547.
37. Teoh CL, Su DD, Sahu S, et al. Chemical fluorescent probe for detection of A β oligomers. *J Am Chem Soc*. 2015;137(42):13503–13509.
38. Matveeva EG, Rudolph A, Moll JR, Thompson RB. Structure-selective anisotropy assay for amyloid beta oligomers. *ACS Chem Neurosci*. 2012;3(11):982–987.
39. Balducci C, Beeg M, Stravalaci M, et al. Synthetic amyloid- β oligomers impair long-term memory independently of cellular prion protein. *Proc Natl Acad Sci U S A*. 2010;107:2295–2300.
40. Freir DB, Nicoll AJ, Klyubin I, et al. Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. *Nat Commun*. 2011;2:1–9.
41. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid- β oligomers. *Nature*. 2009;457:1128–1132.
42. Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid- β (A β) oligomers. *J Biol Chem*. 2010;285: 26377–26383.
43. Fluharty BR, Biasini E, Stravalaci M, et al. An N-terminal fragment of the prion protein binds to amyloid- β oligomers and inhibits their neurotoxicity in vivo. *J Biol Chem*. 2013;288(11):7857–7866.
44. Guillot-Sestier MV, Sunyach C, Ferreira ST, et al. α -Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid β (A β)-associated cell death. *J Biol Chem*. 2012;287(7): 5021–5032.
45. Rushworth JV, Ahmed A, Griffiths HH, et al. A label-free electrical impedimetric biosensor for the specific detection of Alzheimer's amyloid-beta oligomers. *Biosens Bioelectron*. 2014;56:83–90.
46. Xia N, Zhou B, Huang N, Jiang M, Zhang J, Liu L. Visual and fluorescent assays for selective detection of beta-amyloid oligomers based on the inner filter effect of gold nanoparticles on the fluorescence of CdTe quantum dots. *Biosens Bioelectron*. 2016;85:625–632.
47. Li F, Pei H, Wang LH, et al. Nanomaterial-based fluorescent DNA analysis: a comparative study of the quenching effects of graphene oxide, carbon nanotubes, and gold nanoparticles. *Adv Funct Mater*. 2013;23: 4140–4148.
48. Liu L, Sun T, Ren H. Electrochemical detection of hydrogen peroxide by inhibiting the p-benzenediboronic acid-triggered assembly of citrate-capped Au/Ag nanoparticles on electrode surface. *Materials*. 2017;10:40.
49. Pérez-López B, Merkoçi A. Nanoparticles for the development of improved (bio) sensing systems. *Anal Bioanal Chem*. 2011;399(4): 1577–1590.
50. Xia N, Wang X, Wang X, Zhou B. Gold nanoparticle-based colorimetric and electrochemical methods for dipeptidyl peptidase-IV activity assay and inhibitor screening. *Materials*. 2016;9:857.
51. Xu JJ, Zhao WW, Song SP, Fan CH, Chen HY. Functional nanoprobe for ultrasensitive detection of biomolecules: an update. *Chem Soc Rev*. 2014;43(5):1601–1611.
52. Zhu CZ, Yang GH, Li H, Du D, Lin YH. Electrochemical sensors and biosensors based on nanomaterials and nanostructures. *Anal Chem*. 2015;87:230–249.
53. Gan N, Jin HJ, Li TH, Zheng L. Fe₃O₄/Au magnetic nanoparticle amplification strategies for ultrasensitive electrochemical immunoassay of alfa-fetoprotein. *Int J Nanomed*. 2011;6:3259–3269.
54. Feng XB, Gan N, Zhang HR, et al. A novel “dual-potential” electrochemiluminescence aptasensor array using CdS quantum dots and luminol-gold nanoparticles as labels for simultaneous detection of malachite green and chloramphenicol. *Biosens Bioelectron*. 2015;74:587–593.
55. Li H, Sun Z, Zhong W, Hao N, Xu D, Chen HY. Ultrasensitive electrochemical detection for DNA arrays based on silver nanoparticle aggregates. *Anal Chem*. 2010;82(13):5477–5483.
56. Miao P, Meng F, Wang B, Zhu X, Tang Y. Highly sensitive microRNA quantification with zero background signal from silver nanoparticles. *Electrochem Commun*. 2015;51:89–92.
57. Wei T, Dong T, Wang Z, Bao J, Tu W, Dai Z. Aggregation of individual sensing units for signal accumulation: conversion of liquid-phase colorimetric assay into enhanced surface-tethered electrochemical analysis. *J Am Chem Soc*. 2015;137(28):8880–8883.
58. Xia N, Liu L, Chang Y, Hao Y, Wang X. 4-Mercaptophenylboronic acid-induced in situ formation of silver nanoparticle aggregates as labels on an electrode surface. *Electrochem Commun*. 2017;74:28–32.
59. Xia N, Wang X, Zhou B, Wu Y, Mao W, Liu L. Electrochemical detection of amyloid- β oligomers based on the signal amplification of a network of silver nanoparticles. *ACS Appl Mater Interfaces*. 2016;8(30): 19303–19311.
60. Hegnerova K, Bockova M, Vaisocherova H, et al. Surface plasmon resonance biosensors for detection of Alzheimer disease biomarker. *Sens Actuat B Chem*. 2009;139:69–73.
61. Kim JA, Kim M, Kang SM, et al. Magnetic bead droplet immunoassay of oligomer amyloid beta for the diagnosis of Alzheimer's disease using micro-pillars to enhance the stability of the oil-water interface. *Biosens Bioelectron*. 2015;67:724–732.

International Journal of Nanomedicine

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-nanomedicine-journal>

Dovepress

Journal Citation Reports/Science Edition, EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.